Refine by
Psychiatry Articles & Analysis
35 news found
With the advancement of biotechnology and biological tools, such as diagnostic technology and animal model development, researchers can further investigate the mechanisms related to depression and thereby develop effective therapies targeting depression. Ace Therapeutics Psychiatry Team is committed to supporting scientists in making groundbreaking scientific discoveries and ...
With extensive experience in the antipsychiatry industry, the Ace Therapeutics Psychiatry team understands the unique challenges and complexities of developing effective therapies for psychiatric disorders. ...
His background spans a number of therapeutic categories including psychiatry, infectious disease, endocrinology, oncology and allergy. As co-founder and chief development officer of Park Therapeutics, Dr. ...
“With Teva’s strong foundation in neuroscience and our in-house expertise in neurology and psychiatry, this licensing and collaboration agreement adds a promising new compound to our early-stage pipeline as a possible orphan disease treatment for the growing patient population living with multiple system atrophy, as well as a potential option for patients living with ...
Nelson is Professor of Human Genetics, Psychiatry, Pediatrics, Pathology and Laboratory Medicine in the David Geffin School of Medicine at the University of California, Los Angeles. ...
“Cingulate’s approach to ADHD provides medication from proven molecules already available and well understood by providers, but for the first time ever, in a single tablet that is designed to provide entire active-day duration,” said Ann Childress, M.D., President, Center for Psychiatry and Behavior Medicine, Inc., and lead investigator in the CTx-1301 Phase 3 ...
“The first data from CAMP, published last September in Biological Psychiatry, found imbalances in about 17% of children with ASD in amino acids that are important to typical neurodevelopment. ...
Its unique approach is addressing the poor construct validity of behaviourally defined disorders through its proprietary DEPI platform, which integrates molecular data with human genetic information to create testable clinical hypotheses in psychiatry / neuroscience. With multiple clinical proof of concepts, DEPI has allowed for the identification of two distinct subgroups of ...
BySTALICLA
STALICLA's unique approach is addressing the poor construct validity of behaviourally defined disorders through its unique platform integrating molecular data with human genetic information to create testable clinical hypotheses in psychiatry / neuroscience. With multiple clinical proof of concepts, DEPI has allowed for the identification of two distinct subgroups of patients ...
BySTALICLA
(NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that Lumos Pharma management will participate in a panel discussion and host one-on-one meetings at the Cantor Neurology & Psychiatry Conference in October. Event: Cantor Neurology & ...
Douglas Bremner, Professor of Psychiatry and Radiology at Emory University School of Medicine and the primary investigator for the study commented, “Opioid Use Disorder is a crisis across the United States. ...
“We are pleased to continue testing BXCL501 in patients with opioid withdrawal with support from the NIH,” said Dr. Frances Levin, Professor of Psychiatry at Columbia University and Chief of the Division on Substance Use Disorders at New York State Psychiatric Institute/Columbia University, Multiple Principal Investigator of the study and Project Director for the ...
The first patient was enrolled at Butler Hospital, Brown Department of Psychiatry and Human Behavior, Providence, RI. “With treatment-resistant depression, many people struggle to find the medication that works for them, while others never respond to standard treatments,” said Linda Carpenter, MD, a Professor of Psychiatry and Human Behavior in the ...
Presented data at the 2022 Society of Biological Psychiatry (SOBP) Annual Meeting in April and the 2022 International Society for Autism Research (INSAR) Annual Meeting in May demonstrating that in the long-term safety and efficacy study of Zygel in children and adolescents with FXS, improvement was seen in Social Avoidance in the full population, with the greatest improvement in ...
(Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, presented a poster at the 2022 Society of Biological Psychiatry (SOBP) Annual Meeting, held April 28-30, 2022, in New Orleans, La., and virtually. ...
(Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the presentation of a poster at the 2022 Society of Biological Psychiatry (SOBP) Annual Meeting, being held April 28-30, 2022, in New Orleans, La., and virtually. ...
NeuroSigma, Inc., a bioelectronic medical device company, today announced that a team at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London received approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) to commence the largest trial of external Trigeminal Nerve Stimulation (eTNS) ever conducted. ...
Professor of Translational Research and Chair of the Department of Psychiatry at Yale School of Medicine. “The approval of IGALMI, a self-administered film with a desirable onset of action, represents a milestone moment. ...
Jutras-Aswad is the Chief of Staff of the Department of Psychiatry at the Centre hospitalier de l'Université de Montréal (CHUM), where he practices as an Addiction Psychiatrist. ...
“The lack of safe and effective treatment options for co-occurring conditions associated with ASD, such as irritability and anxiety, exacerbate the daily challenges faced by children and their families,” said Robert L. Hendren, D.O., professor, psychiatry, Weill Institute for Neurosciences at the University of California, San Francisco, School of Medicine, and a ...